Perspective Therapeutics (CATX) Times Interest Earned (2010 - 2026)
Perspective Therapeutics' (CATX) quarterly Times Interest Earned came in at 412.08 in Q2 2026, down 103.99% year-over-year from 10318.25 in Q2 2025, and down 53.0% quarter-over-quarter from 269.34 in Q1 2026.
Powered by 
Analysis
Perspective Therapeutics (CATX) Times Interest Earned (2010 - 2026) Analysis & Trends
Perspective Therapeutics has disclosed Times Interest Earned across 11 years of filings, most recently posting 412.08 for Q2 2026.
- In Q2 2026, Times Interest Earned fell 103.99% year-over-year to 412.08; the TTM figure through Jun 2026 stood at 287.92 (up 36.1% YoY), while the FY2025 annual figure was 302.03, up 84.05% from the prior year.
- Times Interest Earned came in at 412.08 for Q2 2026 at Perspective Therapeutics, down from 269.34 in the prior quarter.
- In the past five years, Times Interest Earned ranged from a high of 616.22 in Q4 2024 to a low of 696.43 in Q3 2023.
- Average Times Interest Earned over 4 years is 323.06, with a median of 393.62 recorded in 2023.
- Year-over-year, Times Interest Earned soared 226.66% in 2024 and plunged 103.99% in 2026.
- Over 4 years, Times Interest Earned stood at 486.5 in 2023, then soared by 226.66% to 616.22 in 2024, then sank by 132.78% to 202.01 in 2025, then plunged by 103.99% to 412.08 in 2026.
- Per Business Quant data, the three most recent Times Interest Earned figures were 412.08 in Q2 2026, 269.34 in Q1 2026, and 202.01 in Q2 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 5.22 |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | -42.08 |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 117.59 |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 493.00 |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 2.82 |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | - |
| 10 | Perspective Therapeutics | 361.95 Mn | 361.95 Mn | - | -412.08 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -412.08 |
| Mar 31, 2026 | -269.34 |
| Jun 30, 2025 | -202.01 |
| Mar 31, 2025 | -170.56 |
| Dec 31, 2024 | 616.22 |
| Sep 30, 2024 | -270.06 |
| Jun 30, 2024 | -620.13 |
| Mar 31, 2024 | -448.45 |
| Dec 31, 2023 | -486.50 |
| Sep 30, 2023 | -696.43 |
| Jun 30, 2023 | -375.15 |
| Mar 31, 2023 | -542.28 |
| Jun 30, 2016 | -25,080.00 |
| Sep 30, 2015 | -1,148.42 |
| Jun 30, 2015 | 712.17 |
| Mar 31, 2015 | -10,510.12 |
| Sep 30, 2014 | -336.45 |
| Jun 30, 2014 | -23,577.45 |
| Dec 31, 2013 | -12,143.80 |
| Sep 30, 2013 | -1,666.02 |